Table 3.
Selected studies for locally advanced pancreatic cancer employing chemoradiation ± chemotherapy
| Trial (patients) |
Chemotherapy* | Radiotherapy (Gray) | Median survival (months) | p-value |
|---|---|---|---|---|
| Johnson[59] (129) |
Lithium Gamonelate | - | 5.4 | n.a. |
| Maisey[56] (44/46) |
5/FU PVI 5-FU/MMC |
- | 32% 1 year 43% 1 year |
n.a. |
| Louvet[60] (47/50) |
Gem Gem/Ox |
- -$ |
10.3 10.3 |
p = n.s. |
| Rocha Lima[61] (24/27) |
Gem Gem/Iri |
- -$ |
11.7 9.8 |
p = n.s. |
| Van Cutsem[62] (80/82) |
Gem Gem/tipifarnib |
- | 8.7 11 |
p = n.s. |
| GITSG 1985[77] (25/83/86) |
- 5-FU 5-FU |
60 40 60 |
5.2 9.6 9.2 |
p < 0.01 |
| GITSG 1988[50] (24/24) |
SMF SMF |
54 - |
6.5 5.1 |
p < 0.02 |
| Klaassen[52] (44/47) |
5-FU 5-FU |
40 - |
8.3 8.2 |
n.a. |
| Chauffert[53] (59/60) |
5-FU (PVI)/Cis+Gem Gem |
60 - |
8.0 14.5 |
p = 0.03 |
| Loehrer[55] (36/38) |
Gem + Gem Gem |
50.4 - |
11.0 9.2 |
p = 0.034 |
| Crane[66] (53/61) |
Gem 5-FU (PVI) |
30 (10#) | 11 9 |
p = n.s. |
| Li[78] (18/16) |
Gem 5-FU |
50.4 | 14.5 6.7 |
p = 0.027 |
| Ishii[63] (20) |
5-FU (PVI) | 50.4 | 10.3 | n.a. |
| McGinn[65] (37) |
Gem | 24-42 | 11.6 | n.a. |
| Shinchi[47] (16/15) |
5-FU(PVI) Supportive care |
50.4 - |
13.2 6.4 |
n.a. |
| Brunner[67] (40/42) |
Gem/Cis + Gem Gem/Cis |
55.8 55.8 |
13 8 | p < 0.0001 |
| Huguet[24] (72/56) |
5-FU (PVI)+ as below FolFuGem, GemOx |
55 - |
15 11.7 |
p = 0.0009 |
| Kachnic[64] (23) |
5-FU + Gem | 50.4 | 13 | n.a. |
*: bold and italics indicate chemotherapy given as concurrent chemoradiotherapy #: radiotherapy fraction number; $: a chemotherapy only trial, but very few patients had some radiotherapy; 5-FU: 5-fluorouracil bolus injection unless marked as 'PVI'; Cis: cisplatin; Gem: gemcitabine; Fol: folinic acid; Iri: irinotecan; MMC: mitomycin C; n.a.: not available; n.s.: not significant; Ox: oxaliplatine; PVI: protracted venous infusion, SMF: streptozotocin, mitomycin, 5-fluorouracil.